The global non-invasive prenatal testing market is currently witnessing strong growth. Non-invasive prenatal testing (NIPT) is a form of prenatal screening conducted on a pregnant woman’s blood sample to detect the presence of fetal abnormalities. The test is primarily used to diagnose genetic disorders such as Down syndrome (or trisomy 21), Edwards syndrome (or trisomy 18), Patau syndrome (or trisomy 13) and Turner syndrome, by analyzing DNA fragments in the mother’s blood. The procedure eliminates the need for various precarious and invasive procedures, such as chorionic villus sampling (CVS) and can be performed after nine weeks of pregnancy.
The growing prevalence of genetic disorders of the fetus is one of the key factors driving the market growth. Furthermore, technological advancements in the field of life sciences and healthcare industry is also providing a boost to the market. For instance, the development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have created immense possibilities to combat the chances of any serious disease at the primitive stage itself. Additionally, the increasing acceptance rate for prenatal testing, along with rising health consciousness and awareness regarding the benefits and significance of such testing among the masses, is also driving the market growth. Healthcare providers, as well as expecting parents, are adopting alternatives to diagnose other genetic disorders, including spina bifida, cleft palate, and sickle cell anemia, and treat them in the early stages of fetal development. Moreover, the shifting trend toward childbearing at high maternal age (35 years or older) is also positively impacting the market growth. Advancing maternal age can lead to numerous health complications, such as high blood pressure, reduced fertility, risk of miscarriage and increased risk of chromosomal anomalies in the fetus. Looking forward, IMARC Group expects the market to register a CAGR of around 12% during 2020-2025.
Breakup by Product Type:
Breakup by Test Type:
Breakup by Technology:
Breakup by Test Type:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Berry Genetics Inc., BGI Genomics Co. Ltd., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche AG, GE Healthcare, Igenomix, Illumina Inc., Laboratory Corporation, Natera Inc., Perkinelmer Inc., Thermo Fisher Scientific Inc., Yourgene Health, etc.
Key Questions Answered in This Report:
The global non-invasive prenatal testing market was worth around US$ 3.5 Billion in 2019.
The sudden outbreak of the COVID-19 pandemic, in early 2020, has hampered the market growth due to the high risk of coronavirus contraction upon hospital visits for numerous medical procedures involved in the prenatal testing.
According to the estimates by IMARC Group, the global non-invasive prenatal testing market will exhibit moderate growth during the next five years.
The high prevalence of genetic disorders in the fetus, along with the rising health awareness towards early disease detection at a primitive stage, is primarily driving the demand for non-invasive prenatal testing.
The development of DNA sequencing technologies, regenerative medicines and breakthroughs in molecular research have led to emergence of advanced testing solutions, thereby representing one of the key trends in the non-invasive prenatal testing market.
On the basis of the product type, the market has been bifurcated into consumables, and instruments.
On the basis of the test type, the market has been bifurcated into ultrasound detection, biochemical screening tests, cell-free DNA in maternal plasma tests, fetal cells in maternal blood tests, and others. In this segment, ultrasound detection dominates the global market.
On the basis of the application, the market has been bifurcated into trisomy, microdeletions syndrome, and others, where trisomy holds the largest market share.
Based on the end-user, the market has been segmented into hospitals, diagnostic laboratories, and others, where diagnostic laboratories dominate the global market.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Based on region, North America currently accounts for the largest market share.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at